Duilio Brugnoni

Dr. Duilio Brugnoni

ASST Spedali Civili di Brescia, Brescia, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MAMichael S. Abers
Michael S. Abers
ODOttavia M. Delmonte
Ottavia M. Delmonte
EREmily E. Ricotta
Emily E. Ricotta
JFJonathan Fintzi
Jonathan Fintzi
DFDanielle L. Fink
Danielle L. Fink
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.

1 April 1995 in Nature Genetics
Verified
Journal Article
Closed access
AVAnna Villa
Anna Villa
LNLuigi Notarangelo
Luigi Notarangelo
PMPaolo Macchi
Paolo Macchi
EMElide Mantuano
Elide Mantuano
GCGiovanni Cavagni
Giovanni Cavagni
PVPaolo Vezzoni
Paolo Vezzoni

1 November 1996 in The Lancet
Verified
Journal Article
Closed access
GWGeorg S Wengler
Georg S Wengler
ALArnalda Lanfranchi
Arnalda Lanfranchi
TFTiziana Frusca
Tiziana Frusca
RVRosanna Verardi
Rosanna Verardi
ANArabella Neva
Arabella Neva
AUAg Ugazio
Ag Ugazio

28 April 1994 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
RKRichard A. Kroczek
Richard A. Kroczek
DGDaniel Graf
Daniel Graf
DBDuilio Brugnoni
Duilio Brugnoni
SGSilvia Giliani
Silvia Giliani
UKUlf Korthäuer
Ulf Korthäuer
LNLuigi D. Notarangelo
Luigi D. Notarangelo

1 August 1994 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DBDuilio Brugnoni
Duilio Brugnoni
PAPaolo Airò
Paolo Airò
DGDaniel Gralfu
Daniel Gralfu
MMMassimo Marconiu
Massimo Marconiu
MLMorena Lebowitzu
Morena Lebowitzu
LNLuigi D. Notarangelo
Luigi D. Notarangelo

1 June 2016 in Primary Care Diabetes
Verified
Journal Article
Closed access
GBGraziella Bonetti
Graziella Bonetti
VCVanessa Cancelli
Vanessa Cancelli
GCGiulio Coccoli
Giulio Coccoli
GPGiorgio Piccinelli
Giorgio Piccinelli
DBDuilio Brugnoni
Duilio Brugnoni
MCMariarosa Carta
Mariarosa Carta